课题基金 / 基金详情

Biomarker research in ARDS for predicting response to corticosteroid therapy

Biomarker research in ARDS for predicting response to corticosteroid therapy
ARDS 中预测皮质类固醇治疗反应的生物标志物研究
批准号:
22591732
负责人:
NISHIE Hiroyuki
金额:
$3.0万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2010
资助国家:
日本
项目状态:
已结题
起止时间:
2010 至 2012

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ARDS is a life threatening condition with mortality rates of about 40-60%. We thought that corticosteroids are one of logical choice for treatment of ARDS. A transcriptional factor T-bet, responsible for the induction of T helper (Th)1 cells and the repression of Th2 cells from naive T lymphocytes, is encoded by the gene TBX21. Only one common nonsynonymous TBX21 SNP has been described to date, which codes for a replacement of histidine 33 with glutamine (H33Q). Tantisira KG et al reported that the nonsynonymous variation in TBX21 coding for replacement of H33Q is associated with significant improvement in the PC20 (a measure of airway responsiveness) of asthmatic children. Additionally, Tantisira KG et al alsoreported the TBX21 variant H33Q increases T helper 1 and decreases T helper 2 cytokine expression comparably with wild type H33H. Hence, the TBX21 variant H33Q will have a potential to improve airway responsiveness. Therefore, herein this study, we thought that H33Q in TBX21 will … More also be a predictor for improvement in ARDS with the use of corticosteroids. We developed a Restriction Fragment Length Polymorphism(RFLP) method to examine influence of H33Q of the TBX21 gene to the therapy with corticosteroids in ARDS patients. The status of common nonsynonymous TBX21 SNP was compared with clinical outcome and status of ARDS patients. TBX21 SNP analysis was done in32 cases. Among the 32 patients, 25 (78%) patients showed H33H, 6 (19%) patients showed H33Q, and one patient (3%) showed Q33Q phenotype in the TBX21 gene. In the H33Q/Q33Q group, ARDS patients with functional variant in the TBX21 gene have a possibility to show better outcomes when they treated with some kind of corticosteroids.In addition, we found a case with homozygous functional variant of Q33Q of the TBX21 gene. The case shows dramatic pharmacogenetic response to the therapy with corticosteroids. The PaO2/FiO2 ratio increased from 49 to 220 and pulmonary edema clearly improved after administration of corticosteroids. We found ARDS patients with functional variants in the TBX21 gene, especially Q33Q, have a possibility to show better outcomes when they treated with some kind of corticosteroids. Less
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Can TBX21 c33SNP predict the efficacy of corticosteroid treatment for ARDS?
TBX21 c33SNP 能否预测皮质类固醇治疗 ARDS 的疗效?
DOI: --
发表时间: 2012
期刊:
影响因子: --
作者: [Hiroyuki Nishie, Takeshi Nagasaka, Yoshiko Mori, Hiroshi Morimatsu, et al.]
通讯作者: et al.
TBX21遺伝子コドン33SNPはARDSに対するステロイド効果を予測できるか
TBX21 基因密码子 33 SNP 能否预测类固醇对 ARDS 的影响?
DOI: --
发表时间: 2012
期刊:
影响因子: --
作者: [高橋徹, 森松博史, 川西進, 清水裕子, 森田潔, 西江宏行]
通讯作者: 西江宏行
海外基金